** Shares of PTC Therapeutics PTCT.O fall 1.3% to $45.43 in morning trade
** Company, late on Tuesday, said it has discontinued development of its experimental drug to treat amyotrophic lateral sclerosis (ALS)
** The drug, utreloxastat, failed to slow disease progression, the main goal, in a mid-stage trial - PTCT
** "While this outcome is unfortunate, expectations were low given that drug development in ALS has been difficult and supporting evidence for utreloxastat in ALS was limited" - TD Cowen analysts
** ALS is a rare neurological disease that can break down nerve cells, in the brain and spinal cord, responsible for muscle movements
** Including session moves, stock up about 64% YTD
(Reporting by Mariam Sunny in Bengaluru)
((Mariam.ESunny@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.